301277SZSE

Announcement on Obtaining Drug Registration Certificate

Newland Pharmaceutical Co., Ltd.·May 18, 2026·3 pages

✨ AI Summary

Newland Pharma announces it has received a Drug Registration Certificate from China's National Medical Products Administration for Moxifloxacin Hydrochloride Tablets. This approval grants the company the qualification to produce and sell the drug domestically, enriching its product portfolio and enhancing market competitiveness. The company will adhere to disclosure requirements regarding market performance.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Newland Pharma Co., Ltd. Announcement on Obtaining Drug Registration Certificate

The Company and the Board of Directors guarantee that the information contained in this announcement is true, accurate, and complete, and that there are no false records, misleading statements, or significant omissions.

Newland Pharma Co., Ltd. (hereinafter referred to as the "Company") recently received a Drug Registration Certificate approved and issued by the National Medical Products Administration. The relevant situation is hereby announced as follows:

I. Drug Information

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.